Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 May 2016
Six medicines, including two combination therapies for chronic hepatitis C, recommended for approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use(CHMP) recommended six medicines for approval at its May meeting.
The CHMP recommended granting marketing authorisations in the European Union for two new combination therapies to treat chronic (long-term) hepatitis C, Epclusa(sofosbuvir / velpatasvir) and Zepatier (elbasvir / grazoprevir). For more information please see the press release in the grid below.
Click on this link for more information.
